/CLSD
CLSD Stock - Clearside Biomedical, Inc.
Healthcare|BiotechnologyNASDAQ
$1.00-3.85%
$0.04 (-3.85%) • Dec 16
44
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.49
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.10
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CLSD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.99 – $1.01
TARGET (TP)$1.15
STOP LOSS$0.92
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.79
52W High$17.10
52W Low$0.37
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.66M | $8.23M | $1.33M | $29.57M | $7.89M |
| Gross Profit | $1.51M | $7.87M | $1.12M | $29.57M | $7.89M |
| Gross Margin | 91.0% | 95.7% | 84.6% | 100.0% | 100.0% |
| Operating Income | $-28,882,000 | $-24,844,000 | $-30,277,000 | $-627,000 | $-17,935,000 |
| Net Income | $-34,352,000 | $-32,485,000 | $-32,947,000 | $376,000 | $-18,210,000 |
| Net Margin | -2064.4% | -394.9% | -2482.8% | 1.3% | -230.7% |
| EPS | $-7.05 | $-7.95 | $-8.25 | $0.10 | $-5.85 |
Company Overview
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
40%
Hold / Neutral
3
60%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
2 Bullish3 Neutral/Bearish
Price Targets
$4
Average Target
↑ 333.3% Upside
Now
$2
Low
$4
Average
$6
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 18th 2025 | Stifel | Downgrade | Hold | $2 |
| July 18th 2025 | Chardan Capital Markets | Downgrade | Neutral | - |
| July 18th 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| August 21st 2024 | Chardan Capital Markets | Initiation | Buy | $6 |
| June 25th 2024 | Oppenheimer | Initiation | Outperform | $5 |
Earnings History & Surprises
CLSDBeat Rate
53%
Last 19 quarters
Avg Surprise
-13.4%
EPS vs Estimate
Beats / Misses
10/8
1 met exactly
Latest EPS
$-1.14
Q4 2025
EPS Surprise History
Q1 24
+20.0%
$-0.08vs$-0.10
Q2 24
-21.4%
$-0.17vs$-0.14
Q3 24
+28.6%
$-0.10vs$-0.14
Q4 24
+28.6%
$-0.10vs$-0.14
Q1 25
+23.1%
$-0.10vs$-0.13
Q2 25
+8.3%
$-0.11vs$-0.12
Q3 25
+50.0%
$-0.90vs$-1.80
Q4 25
-70.1%
$-1.14vs$-0.67
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.75 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.67 | $-1.14 | -70.1% | ✗ MISS |
Q3 2025 | Aug 8, 2025 | $-1.80 | $-0.90 | +50.0% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.12 | $-0.11 | +8.3% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-0.13 | $-0.10 | +23.1% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.14 | $-0.10 | +28.6% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.14 | $-0.10 | +28.6% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.14 | $-0.17 | -21.4% | ✗ MISS |
Q1 2024 | Mar 12, 2024 | $-0.10 | $-0.08 | +20.0% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.16 | $-0.15 | +6.3% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.14 | $-0.15 | -7.1% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.14 | $-0.15 | -7.1% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $-0.13 | $-0.16 | -23.1% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.03 | $-0.13 | -282.4% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.13 | $-0.13 | 0.0% | = MET |
Q2 2022 | May 11, 2022 | $-0.08 | $-0.13 | -58.5% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $0.16 | $0.31 | +93.8% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-0.12 | $-0.11 | +8.3% | ✓ BEAT |
Q2 2021 | May 17, 2021 | $-0.08 | $-0.13 | -62.5% | ✗ MISS |
Latest News
Clearside Biomedical shares are trading lower after the company recently announced it filed a voluntary petition for bankruptcy.
📉 NegativeBenzinga•Nov 28, 2025, 04:57 PM
Clearside Biomedical shares are trading lower after the company announced it filed a voluntary petition for bankruptcy.
📉 NegativeBenzinga•Nov 24, 2025, 02:07 PM
Clearside Biomedical files for Chapter 11
📉 NegativeSeeking Alpha•Nov 24, 2025, 12:28 PM
Clearside Biomedical Filed A Voluntary Petition For Bankruptcy
📉 NegativeBenzinga•Nov 24, 2025, 12:15 PM
Needham Reiterates Hold on Clearside Biomedicalto Hold
➖ NeutralBenzinga•Nov 18, 2025, 03:38 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Sep 12, 2025, 11:50 PM
Clearside To Showcase Versatility Of SCS Microinjector And CLS-AX Programs For Retinal Diseases At EURETINA 2025
📈 PositiveBenzinga•Aug 26, 2025, 12:11 PM
Frequently Asked Questions about CLSD
What is CLSD's current stock price?
Clearside Biomedical, Inc. (CLSD) is currently trading at $1.00 per share. The stock has moved -3.85% today.
What is the analyst price target for CLSD?
No analyst price targets are currently available for this stock.
What sector is Clearside Biomedical, Inc. in?
Clearside Biomedical, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CLSD's market cap?
Clearside Biomedical, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does CLSD pay dividends?
No, Clearside Biomedical, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALLR
Allarity Therapeutics, Inc.
$1.03
Mkt Cap: $0.0B
CASI
CASI Pharmaceuticals, Inc.
$0.81
Mkt Cap: $0.0B
CING
Cingulate Inc.
$3.97
Mkt Cap: $0.0B
ENTO
Entero Therapeutics, Inc.
$1.98
Mkt Cap: $0.0B
KAPA
Kairos Pharma, Ltd.
$0.86
Mkt Cap: $0.0B
LEXX
Lexaria Bioscience Corp.
$0.58
Mkt Cap: $0.0B
LSTA
Lisata Therapeutics, Inc.
$2.06
Mkt Cap: $0.0B
MTVA
MetaVia Inc.
$8.62
Mkt Cap: $0.0B
PALI
Palisade Bio, Inc.
$1.83
Mkt Cap: $0.3B
PTHS
Pelthos Therapeutics Inc.
$25.63
Mkt Cap: $0.0B
Explore stocks similar to CLSD for comparison